CORE--MACROMOLECULAR ANALYSIS FACILITY

高分子分析设备由三个独立的，但 相关实体：DNA测序设施（DSF）， 自动化DNA测序，自动化微卫星分析，和单- 链构象多态性（SSCP）分析;计算 分析设施（CAF），帮助调查人员进行计算 大分子结构分析和核酸核心设施 （NACF），一个集中实验室，用于标准化DNA提取， 转基因小鼠的各种来源和基因分型。这些资源 从血液、肿瘤样品和石蜡包埋或冷冻的样品中制备DNA， 切片（在NACF中）;确定DNA序列并进行微卫星 和SSCP分析（在DSF中）。DNA序列由CAF分析。的 DSF在基础、临床和医学领域为广泛的研究者提供帮助。 以人口为基础的研究，涉及生长控制、生长 抑制、对特定细胞谱系的定型、细胞粘附和 流动性、转移、血管生成等领域，以及支持 研究新的癌症易感基因的定位和克隆， 筛查已知癌症中的肿瘤和组成突变 易感基因与肿瘤及体质突变筛查 在已知的癌症易感基因和肿瘤筛查中， 已知癌症易感基因的组成突变， 致癌基因DSF提供快速可靠的序列信息， 调查人员以高效率和具有成本效益的方式。DNA的数量 由DSF确定的序列从1992年的约1,500个增加了400%， 1996年7月1日至1997年6月1日， 可读序列从约300 - 350增加到超过650个碱基， sample.为了生成DS序列，DSF目前在ABI 373上使用 DNA测序仪配备了拉伸配置和一个最近 获得ABI 377 DNA测序仪。该资源为调查人员提供了 聚合酶链反应（PCR）生成的DNA，以产生最多的 精确的DNA序列和引物设计和维护方面的专业知识 严格的质量控制，确保服务的一致性。大幅 该设施致力于确定最佳条件， 使用新的和改进的荧光染料进行DNA测序， 内切酶该设施最近开始使用ABI 377 DNA测序仪， PCR产物的大小和数量的自动分析。分析 检测PCR产物中的SSCP，并允许进行遗传连锁分析， 确定特定微卫星的大小和数量， PCR产物。377 ABI DNA测序仪也用于执行 微卫星分析，以评估体质和肿瘤特异性 基因组不稳定性

The Macromolecular Analysis Facility consists of three separate but related entities: the DNA Sequencing Facility (DSF), which performs automated DNA sequencing, automated microsatellite analysis, and single- strand conformation polymorphism (SSCP) analysis; the Computational Analysis Facility (CAF), which helps investigators with computational analysis of macromolecular structures; and the Nucleic Acid Core Facility (NACF), a centralized laboratory for standardized DNA extraction from various sources and genotyping of transgenic mice. These resources prepared DNA from blood, tumor samples, and paraffin-embedded or frozen sections (in the NACF); determine DNA sequences and perform microsattelite and SSCP analyses (in the DSF). DNA sequences are analyzed by the CAF. The DSF provides help to a wide range of investigators in basic, clinical and population-based research involved in studies of growth control, growth inhibition, commitment to specific cell lineages, cell adhesion and mobility, metastasis, angiogenesis, and other fields, as well as supports studies on the mapping and cloning of new cancer susceptibility genes and screening for tumor and constitutional mutations in known cancer susceptibility genes and screening for tumor and constitutional mutations in known cancer susceptibility genes and screening for tumor and constitutional mutations in known cancer susceptibility genes and oncogenes. The DSF provides fast and reliable sequence information to investigators in an efficient and cost-effective manner. The number of DNA sequences determined by the DSF increased 400% from about 1,500 in 1992 to over 6,000 between July 1, 1996 and June 1, 1997, and the length of readable sequences increased from about 300-350 to more than 650 bases per sample. To generate the DS sequences, the DSF currently uses on ABI 373 DNA sequencer equipped with stretch configuration and one recently acquired ABI 377 DNA sequencer. The resource provides investigators with the polymerase chain reaction (PCR)-generated DNAs, to produce the most accurate DNA sequences and expertise in primer design and maintain rigorous quality control to ensure consistency of service. A substantial effort of the facility is dedicated to determining optimal conditions for DNA sequencings with new and improved fluorescent dyes and more efficient enzymes. The facility recently began to use the ABI 377 DNA sequencer for automated analysis of the sizes and amounts of PCR products. The analysis detects SSCPs in PCR products and allows genetic linkage analysis by determining the sizes and amounts of specific microsatellite-containing PCR products. The 377 ABI DNA sequencer is also used to perform microsatellite analysis to evaluate constitutional and tumor-specific genomic instability.